BACKGROUND: Diabetes mellitus promotes atrial structural remodeling, thereby producing atrial arrhythmogenicity, where advanced glycation endproducts (AGEs) and their receptor (RAGE) are implicated to play a role in the pathogenesis. PURPOSE: We investigated the effects of candesartan, an angiotensin type II receptor blocker, on the diabetes-induced atrial structural change. METHODS AND RESULTS: Diabetes was induced in 8-week-old female Sprague-Dawley rats by intraperitoneal injection of streptozotocin at 70 mg/kg. Osmotic pumps were simultaneously set to infuse candesartan at a subdepressor dose of 0.05 mg/kg/day. Twelve weeks after the induction of diabetes, the blood glucose and glycated hemoglobin A1c were significantly higher in streptozotocin-injected rats than those in control rats, and were not affected by candesartan treatment. The atria of diabetic rats showed remarkable diffuse interstitial fibrosis with more enhanced protein expressions of RAGE and connective tissue growth factor (CTGF) compared with control ones. The treatment with candesartan significantly reduced CTGF expression and effectively suppressed the development of fibrotic deposition in diabetic animals. CONCLUSIONS: Candesartan reduced CTGF expression and attenuated the fibrosis in diabetic rat atria. These results implied the protective effects of candesartan on diabetes-related atrial arrhythmias.
BACKGROUND:Diabetes mellitus promotes atrial structural remodeling, thereby producing atrial arrhythmogenicity, where advanced glycation endproducts (AGEs) and their receptor (RAGE) are implicated to play a role in the pathogenesis. PURPOSE: We investigated the effects of candesartan, an angiotensin type II receptor blocker, on the diabetes-induced atrial structural change. METHODS AND RESULTS:Diabetes was induced in 8-week-old female Sprague-Dawley rats by intraperitoneal injection of streptozotocin at 70 mg/kg. Osmotic pumps were simultaneously set to infuse candesartan at a subdepressor dose of 0.05 mg/kg/day. Twelve weeks after the induction of diabetes, the blood glucose and glycated hemoglobin A1c were significantly higher in streptozotocin-injected rats than those in control rats, and were not affected by candesartan treatment. The atria of diabeticrats showed remarkable diffuse interstitial fibrosis with more enhanced protein expressions of RAGE and connective tissue growth factor (CTGF) compared with control ones. The treatment with candesartan significantly reduced CTGF expression and effectively suppressed the development of fibrotic deposition in diabetic animals. CONCLUSIONS:Candesartan reduced CTGF expression and attenuated the fibrosis in diabeticrat atria. These results implied the protective effects of candesartan on diabetes-related atrial arrhythmias.
Authors: M Del Carmen Ortiz; Silvia Lores-Arnaiz; M Florencia Albertoni Borghese; Sabrina Balonga; Agustina Lavagna; Ana Laura Filipuzzi; Daniela Cicerchia; Monica Majowicz; Juanita Bustamante Journal: Neurochem Res Date: 2013-11-05 Impact factor: 3.996
Authors: Iuliia Polina; Hailey J Jansen; Tiesong Li; Motahareh Moghtadaei; Loryn J Bohne; Yingjie Liu; Pooja Krishnaswamy; Emmanuel E Egom; Darrell D Belke; Sara A Rafferty; Martin Ezeani; Anne M Gillis; Robert A Rose Journal: Proc Natl Acad Sci U S A Date: 2020-03-20 Impact factor: 11.205
Authors: María C Ortiz; María F Albertoni Borghese; Sabrina E Balonga; Agustina Lavagna; Ana L Filipuzzi; Rosana Elesgaray; María A Costa; Mónica P Majowicz Journal: PLoS One Date: 2014-08-11 Impact factor: 3.240
Authors: Martin Aguilar; Robert A Rose; Abhijit Takawale; Stanley Nattel; Svetlana Reilly Journal: Cardiovasc Res Date: 2021-06-16 Impact factor: 10.787